Alle Studien
Aktiv, aber nicht rekrutierendPHASE2INTERVENTIONELL

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

This study is a clinical trial looking at a new medicine called volixibat. It's for people who have a liver condition called Primary Sclerosing Cholangitis (PSC) and are troubled by itching. Researchers want to find out if volixibat is safe and if it can help reduce this itching. They also want to understand if the medicine might have an effect on the overall progression of PSC. Patients in the study will either receive volixibat or a dummy medicine (placebo). This research is currently in Phase 2, which means it’s still an early stage where doctors are mainly checking for safety and how well the medicine works.

Auf einen Blick

Status
Aktiv, aber nicht rekrutierend
Phase
PHASE2
Sponsor
Mirum Pharmaceuticals, Inc.
Einschreibeziel
182
Starten
18 Dez 2020
Geschätzte Fertigstellung
01 Mar 2028

Worum geht es in dieser Studie?

This clinical trial is all about a new investigational medicine called volixibat. Doctors are studying it because they want to find better ways to help people who have a liver condition called Primary Sclerosing Cholangitis, or PSC, especially if they experience persistent and bothersome itching. PSC is a chronic disease that affects the bile ducts in the liver. These ducts can become inflamed and scarred, which can lead to various symptoms, including severe itching. The research team wants to see if volixibat can ease this itching for people with PSC. They will also be looking to see if the medicine has any impact on how the disease develops over time, which is very important for people living with PSC. In this study, some participants will receive the investigational medicine, volixibat, while others will receive a placebo. A placebo is a dummy treatment that looks just like the real medicine but contains no active ingredients. This helps researchers to fairly compare the effects of volixibat. This is a Phase 2 study, which means it's an important step where the medicine's safety and effectiveness are being carefully evaluated.

Wichtige Erkenntnisse

  • This study is testing a new medicine, volixibat, for itching related to PSC.
  • It aims to see if volixibat is safe and effective for this type of itching.
  • The study also looks at how the medicine might affect PSC progression.
  • Some participants will receive the active medicine; others will receive a placebo.
  • It's a Phase 2 study, focusing on early safety and effectiveness.
  • Your participation is voluntary, and you can withdraw at any time.

Wer könnte berechtigt sein?

To join this study, you would need to be at least 12 years old if you live in certain areas, or 18 years old in others. You must have a confirmed diagnosis of PSC and be experiencing bothersome itching because of it. If you're already taking medicines for PSC or to help with itching, or if you also have Inflammatory Bowel Disease (IBD), you might still be able to join under certain conditions.

However, some things would prevent you from taking part. For example, if your itching is caused by something other than PSC, or if you have severe liver problems or a history of certain surgeries that affect your digestive system, you wouldn't be able to join. Also, if you've recently had certain procedures on your bile ducts or if some of your blood test results are outside a specific range, you might not be eligible.

It's important that you understand and agree to all the study requirements, including attending all visits and follow-up appointments.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. I have been diagnosed with Primary Sclerosing Cholangitis (PSC).
  2. I experience bothersome itching because of my PSC.
  3. I am at least 12 years old (or 18, depending on location).
  4. I am generally in stable health and don't have very severe liver problems.
  5. I am willing and able to attend all study appointments and follow instructions.
  6. I haven't had recent surgery that affected my digestive system in a major way.
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you decide to take part in this study, you will first have screening appointments to make sure you meet all the requirements. Throughout the study, you'll have regular visits to the clinic where doctors will monitor your health, check for any changes in your itching, and take blood samples. You will be given either the study medicine, volixibat, or a placebo, and you'll need to take it as instructed. There will also be follow-up appointments after you stop taking the study medicine to ensure your well-being. The total duration of your involvement in the study, including follow-up, will be explained in detail by the study team.

Potenzielle Risiken und Vorteile

Participating in this study might offer potential benefits, such as gaining access to a new investigational medicine that could help reduce your itching from PSC. You'd also be contributing valuable information that could help others with PSC in the future. However, there are potential risks, as with any new medicine. Volixibat might cause side effects, and these will be carefully explained to you. You'll receive close medical monitoring throughout the study. Remember, joining is entirely voluntary, and you have the right to withdraw from the study at any time without affecting your medical care.

Locations (103)

  • Southern California Research Center
    Verifizierte Postleitzahl
    Coronado, United States
  • Cedars Sinai Medical Center
    Verifizierte Postleitzahl
    Los Angeles, Vereinigte Staaten
  • University of California, Davis
    Verifizierte Postleitzahl
    Sacramento, Vereinigte Staaten
  • California Pacific Medical Center Research Institute
    Verifizierte Postleitzahl
    San Francisco, Vereinigte Staaten
  • University of Colorado - Anschutz Medical Campus
    Verifizierte Postleitzahl
    Aurora, Vereinigte Staaten
  • MedStar Georgetown University Hospital
    Verifizierte Postleitzahl
    Washington D.C., Vereinigte Staaten
  • Florida Research Institute
    Verifizierte Postleitzahl
    Lakewood Rch, United States
  • University of Miami - Schiff Center for Liver Diseases
    Verifizierte Postleitzahl
    Miami, Vereinigte Staaten
  • Tampa General Hospital
    Verifizierte Postleitzahl
    Tampa, Vereinigte Staaten
  • Beth Israel Deaconess Medical Center
    Verifizierte Postleitzahl
    Boston, Vereinigte Staaten
  • Henry Ford Hospital
    Verifizierte Postleitzahl
    Detroit, Vereinigte Staaten
  • Mayo Clinic
    Verifizierte Postleitzahl
    Rochester, Vereinigte Staaten

Häufige Fragen

What is PSC?

PSC, or Primary Sclerosing Cholangitis, is a long-term liver disease where the bile ducts gradually become inflamed and scarred, which can lead to symptoms like itching.

What is volixibat?

Volixibat is an investigational medicine being tested in this study to see if it can help reduce itching in people with PSC and affect how the disease progresses.

Was ist ein Placebo?

A placebo is a 'dummy' medicine that looks like the real thing but doesn't contain any active drug. It's used in studies to compare the effects of the actual medicine fairly.

Werde ich wissen, ob ich das echte Medikament oder das Placebo erhalte?

No, during the main part of the study, neither you nor your doctors will know whether you are receiving volixibat or the placebo. This is to ensure the study results are unbiased.

What 'phase' is this study?

This is a Phase 2 study. This means it's an early stage where doctors are mainly checking for the medicine's safety and how well it works.

Wie Sie mehr erfahren können

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.